Who are we?

TRACTIVUS emerges as a spin-off from the research group GEMAT (IQS-Ramón Llull University) and IDIBELL (Bellvitge Biomedical Research Institute) in order to avoid bacterial colonization in medical devices.

 

Developing and providing infection-control solutions for long-lasting devices, Tractivus can reduce healthcare-acquired infections. Less infections reduce complications, hospital stays and the use of antibiotics, thus reducing resource allocation and costs for healthcare. Focusing on people, Tractivus provides a tool to improve the work of health professionals and the life quality of patients.

PHOBOSTech technology have been developed over the years as a final solution to the current problems of medical devices. Our cost-effective patented technology allows to create nanostructures on the surface, preventing bacteria attachment and, therefore, bacteria colonization. As a result our devices show higher lifetime, lower associated costs, and no post-implantation problems without adverse effect on the patients.

Tractivus combines the experience of the research groups and a unique solution designed to root out the colonization of the devices through a micro- and nano-structured coating that protects the device from adhesion and bacterial colonization. The team has worked on all aspects of the development: material selection, regulatory strategy, risk reduction, clinical trials, partners, stakeholders... aiming to maximize  the success of both the project and the investors.

logo_B&W.png

If you want to contact us do not hesitate to call us, send us an email or use our social media.

  • email
  • LinkedIn - círculo blanco
  • White Twitter Icon
  • White Facebook Icon

+34 932 672 000

 

Via Augusta, 394

Barcelona (08017)

Spain
 

Follow us!
  • Twitter
  • Icono social LinkedIn

Funded by:

Copyright © 2020 TRACTIVUS SL. All rights reserved.

 | 

 |